Altus Appoints Dr. Anton Hoos Vice President of Pharmaceutical Development.Business Editors/Health/Medical Writers BIOWIRE2K CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nov. 21, 2003 Altus(R) Biologics Inc., a pharmaceutical company developing novel oral enzyme replacement therapies, has appointed Anton Hoos, M.D., to the newly created position of Vice President of Pharmaceutical Development. Dr. Hoos will oversee Altus' product development activities. His responsibilities will include project management, clinical R&D, regulatory affairs Regulatory Affairs (RA), also called Government Affairs, is a profession within regulated industries, such as pharmaceuticals, medical devices, energy, and banking. Regulatory Affairs professionals usually have responsibility for the following general areas: mal·ab·sorp·tion n. Defective or inadequate absorption of nutrients from the intestinal tract. as a result of exocrine pancreatic insufficiency Exocrine pancreatic insufficiency (EPI) is the inability to properly digest food due to a lack of digestive enzymes made by the pancreas. This disease is found frequently in dogs. EPI is also found in humans afflicted with cystic fibrosis. . "Altus is very pleased to welcome Dr. Hoos to our senior management team," said Peter Lanciano, Chief Executive Officer and President of Altus. "With his broad industry expertise in global biological product development, Dr. Hoos will strengthen Altus' capabilities as the company moves several products through development to commercialization. Dr Hoos' experience in global product development, regulatory approval and commercial product launches will play a critical role as Altus enters into an advanced international phase II trial for our lead product. Dr. Hoos will also actively be involved with our corporate manufacturing partner as a commercial launch facility comes on line. Altus has several products at various stages of development, that address the unmet medical needs of patients with gastrointestinal and metabolic diseases, which will benefit from Dr. Hoos' insight and depth of experience." Prior to joining Altus, Dr. Hoos had been with Aventis Behring and its predecessor companies for 13 years. Dr. Hoos brings to Altus significant experience in the global development of therapeutic proteins. Dr. Hoos while at Aventis Behring, led multiple product development and life cycle management efforts, which resulted in product approvals with the FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. , EMEA (Europe, Middle East, Africa) Refers to that region of the world. For example, one might see products packaged differently for the UK, EMEA and Asia Pacific markets. and the Japanese MHLW MHLW Ministry of Health, Labor and Welfare (Japan; formerly Ministry of Health and Welfare, MHW) MHLW Mean High Low Water (tide level) . Products developed under his leadership are in the therapeutic areas of coagulation coagulation (kōăg'y  lā`shən), the collecting into a mass of minute particles of a solid dispersed throughout a liquid (a sol), usually followed by the precipitation or , wound healing wound healing Physiology The repair of a wound Steps Inflammation, repair and closure, remodeling, final healing; repair of incisions may be either simple–'clean' wounds with little loss of tissue heal by 'primary intention', or 'dirty' wounds heal by , immunology and critical care and include trade names such as Humate P(TM), Zemaira(TM) and Beriplast P(TM). At Aventis Behring, Dr. Hoos chaired the Corporate Innovation Management Team and served as Vice President for Global Project and Life Cycle Management with responsibility for all projects in drug development as well as all life cycle management programs for licensed products. Dr. Hoos received an M.D. from the University of Munich and an M.B.A from the University of Toronto Research at the University of Toronto has been responsible for the world's first electronic heart pacemaker, artificial larynx, single-lung transplant, nerve transplant, artificial pancreas, chemical laser, G-suit, the first practical electron microscope, the first cloning of T-cells, . About Altus(R) Altus is a pharmaceutical company that uses its proprietary protein crystallization Crystallization The formation of a solid from a solution, melt, vapor, or a different solid phase. Crystallization from solution is an important industrial operation because of the large number of materials marketed as crystalline particles. technology to develop innovative, orally delivered enzyme replacement therapies to treat a number of significant unmet medical needs in the areas of gastrointestinal and metabolic diseases. Altus' protein crystallization technology, known as Crystalomics(TM), enables the rapid commercialization of high-value orally delivered protein-based products by creating highly stable and potent protein therapeutics. The technology enables oral delivery of the protein to the gastrointestinal tract gastrointestinal tract n. The part of the digestive system consisting of the stomach, small intestine, and large intestine. Gastrointestinal tract to provide a localized or topical effect within the gastrointestinal lumen. These products are novel therapies that are designed to be safe, effective and convenient for patients. Through its product portfolio, the Company's vision is to be the worldwide leader in the rapid and efficient development of valuable oral enzyme replacement therapies for the treatment of gastrointestinal and metabolic diseases. The Company has a series of products in various stages of research and development, all leveraging the Crystalomics technology. Altus has numerous development partners and is constantly evaluating the opportunity to expand its product development efforts through partnering opportunities. For more information about TheraCLEC and for upcoming clinical trials you can contact the Altus Medical Product Information Department at (617) 299-2900. Humate P(TM), Zemaira(TM) and Beriplast P(TM) are licensed trademarks of Aventis Behring |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion